Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and BO-112 for Resectable Soft Tissue Sarcoma
NCT04420975Phase 1Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2020
- Primary completion
- Jan 2027
- Modality
- Oncolytic Viruses, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nanoplexed poly I:C in soft tissue sarcoma (STS), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events. Started Oct 2020; status: active, not recruiting.
02
Drugs
nanoplexed poly I:C
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04420975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04420975.